Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 1.94 | 2.13 | 7.50 | 6.11 | 3.37 | 2.65 | 3.45 |
Net Debt/EBITDA |
— | (3.21) | (0.47) | 1.95 | 0.96 | 0.59 | 0.47 | 0.78 |
Debt/Assets |
0.00% | 802.09% | 180.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (1.02) | (1.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.35 | 0.28 | 0.22 | 0.87 | 0.62 | 0.84 | 1.05 |
Capex/Depreciation |
— | 0.00 | (0.01) | (0.06) | (0.73) | (0.58) | (0.01) | 0.04 |
Interest Coverage |
— | (2.51) | (9.94) | (32.02) | (1,555.39) | (1,878.67) | (2,158.64) | (3,676.85) |
| — | 13.84% | 19.07% | 192.16% | (46.76%) | (79.69%) | (157.19%) | (88.60%) | |
| — | (234.94%) | (165.63%) | (49.05%) | (39.06%) | (60.26%) | (103.89%) | (59.75%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (232.04%) | (312.04%) | (31.69%) | (53.38%) | (105.96%) | (182.70%) | (68.76%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.14) | (6.78) | (0.70) | (0.79) | (0.54) | (0.72) | (0.34) |
Cash per Share |
— | 0.13 | 10.21 | 10.54 | 1.76 | 1.00 | 0.63 | 0.51 |
Shareholders Equity per Share |
— | (2.66) | (25.22) | 9.88 | 1.70 | 0.82 | 0.47 | 0.47 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (2.66) | (25.22) | 9.88 | 1.70 | 0.82 | 0.47 | 0.47 |
Free Cash Flow |
— | (3.10) | (3.44) | (3.66) | (18.70) | (16.16) | (28.48) | (24.58) |
Working Capital |
— | 3.48 | 3.66 | 51.13 | 39.85 | 24.05 | 18.41 | 34.07 |
Capital Expenditures |
— | (0.14) | (0.01) | (0.03) | (0.17) | (0.15) | 0.00 | 0.01 |
Net Current Asset Value |
— | (58.72) | (13.02) | 51.13 | 37.47 | 23.53 | 18.07 | 33.87 |
| Other line items | ||||||||
Quick Ratio |
— | 1.90 | 1.95 | 7.25 | 5.80 | 3.07 | 2.49 | 3.37 |
Depreciation/Fixed assets |
— | 0.27 | 4.43 | 3.28 | 1.01 | 0.89 | 1.47 | 2.45 |
Cash ROIC |
— | (72.11%) | (65.87%) | (3.45%) | (22.86%) | (29.72%) | (65.08%) | (34.49%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 10,621.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.14) | (6.76) | (0.70) | (0.78) | (0.53) | (0.72) | (0.34) |
Capex per Share |
— | 0.00 | (0.02) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 2.64 | 2.64 | 1.71 | 2.97 | 2.48 | 1.98 | 6.30 |
Average Payables |
— | 2.18 | 2.18 | 3.09 | 3.69 | 3.46 | 2.84 | 1.55 |
Average Assets |
— | 3.73 | 7.29 | 33.13 | 54.78 | 42.79 | 32.70 | 39.31 |
Average Common Equity |
— | (63.30) | (63.30) | (8.46) | 45.76 | 32.36 | 21.61 | 26.51 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates